150 related articles for article (PubMed ID: 38325328)
1. A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma.
Yu S; Yu M; Keane B; Mauro DM; Helft PR; Harris WP; Sanoff HK; Johnson MS; O'Neil B; McRee AJ; Somasundaram A
Oncologist; 2024 Mar; 29(3):270-e413. PubMed ID: 38325328
[TBL] [Abstract][Full Text] [Related]
2. A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma.
Lee YB; Nam JY; Cho EJ; Lee JH; Yu SJ; Kim HC; Paeng JC; Yoon JH; Kim YJ
Clin Cancer Res; 2023 Sep; 29(18):3650-3658. PubMed ID: 37459133
[TBL] [Abstract][Full Text] [Related]
3. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization.
Xing M; Kokabi N; Camacho JC; Kim HS
BMC Cancer; 2018 Jan; 18(1):75. PubMed ID: 29329568
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort.
Das A; Riaz A; Gabr A; Ali R; Mora R; Al Asadi A; Mouli S; Lewandowski RJ; Salem R
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):807-815. PubMed ID: 31502015
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection.
Ali R; Riaz A; Gabr A; Abouchaleh N; Mora R; Al Asadi A; Caicedo JC; Abecassis M; Katariya N; Maddur H; Kulik L; Lewandowski RJ; Salem R
Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2195-2202. PubMed ID: 28812136
[TBL] [Abstract][Full Text] [Related]
6. Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.
Gordon AC; Gabr A; Riaz A; Uddin OM; Abouchaleh N; Ali R; Kallini J; Salem R; Lewandowski RJ
Cardiovasc Intervent Radiol; 2018 Oct; 41(10):1557-1565. PubMed ID: 29948005
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial.
Verset G; Borbath I; Karwal M; Verslype C; Van Vlierberghe H; Kardosh A; Zagonel V; Stal P; Sarker D; Palmer DH; Vogel A; Edeline J; Cattan S; Kudo M; Cheng AL; Ogasawara S; Daniele B; Chan SL; Knox JJ; Qin S; Siegel AB; Chisamore M; Hatogai K; Wang A; Finn RS; Zhu AX
Clin Cancer Res; 2022 Jun; 28(12):2547-2554. PubMed ID: 35421228
[TBL] [Abstract][Full Text] [Related]
8. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
[TBL] [Abstract][Full Text] [Related]
9. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial.
Tai D; Loke K; Gogna A; Kaya NA; Tan SH; Hennedige T; Ng D; Irani F; Lee J; Lim JQ; Too CW; Ng MCH; Tham CK; Lam J; Koo SL; Chong HS; Goh GB; Huang HL; Venkatanarasimha N; Lo R; Chow PKH; Goh BKP; Chung A; Toh HC; Thng CH; Lim TKH; Yeong J; Zhai W; Chan CY; Choo SP
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1025-1035. PubMed ID: 34695377
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization.
Levey AO; Elsayed M; Lawson DH; Ermentrout RM; Kudchadkar RR; Bercu ZL; Yushak ML; Newsome J; Kokabi N
Cardiovasc Intervent Radiol; 2020 Feb; 43(2):254-263. PubMed ID: 31686137
[TBL] [Abstract][Full Text] [Related]
11. Radioembolization for hepatocellular carcinoma using TheraSphere®.
Ali SM
Saudi J Gastroenterol; 2011; 17(3):215-7. PubMed ID: 21546728
[TBL] [Abstract][Full Text] [Related]
12. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
El Fouly A; Ertle J; El Dorry A; Shaker MK; Dechêne A; Abdella H; Mueller S; Barakat E; Lauenstein T; Bockisch A; Gerken G; Schlaak JF
Liver Int; 2015 Feb; 35(2):627-35. PubMed ID: 25040497
[TBL] [Abstract][Full Text] [Related]
13. Patient Selection and Clinical Outcomes of Y90 in Hepatocellular Carcinoma.
Wehrenberg-Klee E; Gandhi RT; Ganguli S
Tech Vasc Interv Radiol; 2019 Jun; 22(2):70-73. PubMed ID: 31079713
[TBL] [Abstract][Full Text] [Related]
14. Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma.
Chow PK; Poon DY; Khin MW; Singh H; Han HS; Goh AS; Choo SP; Lai HK; Lo RH; Tay KH; Lim TG; Gandhi M; Tan SB; Soo KC;
PLoS One; 2014; 9(3):e90909. PubMed ID: 24614178
[TBL] [Abstract][Full Text] [Related]
15. Response Assessment by Volumetric Iodine Uptake Measurement: Preliminary Experience in Patients with Intermediate-Advanced Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization.
Bargellini I; Crocetti L; Turini FM; Lorenzoni G; Boni G; Traino AC; Caramella D; Cioni R
Cardiovasc Intervent Radiol; 2018 Sep; 41(9):1373-1383. PubMed ID: 29654507
[TBL] [Abstract][Full Text] [Related]
16. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent?
Zu Q; Schenning RC; Jahangiri Y; Tomozawa Y; Kolbeck KJ; Kaufman JA; Al-Hakim R; Naugler WE; Nabavizadeh N; Kardosh A; Billingsley KG; Mayo SC; Orloff SL; Enestvedt KK; Maynard E; Ahn J; Lhewa D; Farsad K
Cardiovasc Intervent Radiol; 2020 May; 43(5):721-731. PubMed ID: 32140840
[TBL] [Abstract][Full Text] [Related]
17. Ablative Transarterial Radioembolization Improves Survival in Patients with HCC and Portal Vein Tumor Thrombus.
Cardarelli-Leite L; Chung J; Klass D; Marquez V; Chou F; Ho S; Walton H; Lim H; Tae Wan Kim P; Hadjivassiliou A; Liu DM
Cardiovasc Intervent Radiol; 2020 Mar; 43(3):411-422. PubMed ID: 31909439
[TBL] [Abstract][Full Text] [Related]
18. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib.
Teyateeti A; Mahvash A; Long J; Abdelsalam M; Avritscher R; Kaseb A; Odisio B; Ravizzini G; Surasi D; Teyateeti A; Macapinlac H; Kappadath SC
World J Gastroenterol; 2021 Dec; 27(47):8166-8181. PubMed ID: 35068861
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome analysis of Y90 radioembolization in hepatocellular carcinoma.
Lee HM; Alder L; Nguyen M; Dougherty SC; Qu Y; Thacker LR; Poklepovic A
J Gastrointest Oncol; 2023 Jun; 14(3):1378-1391. PubMed ID: 37435218
[TBL] [Abstract][Full Text] [Related]
20. Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children.
Aguado A; Ristagno R; Towbin AJ; Gupta A; Haberle S; Qi Z; Patel MN; Kukreja KU; Tiao GM; Geller JI
Pediatr Blood Cancer; 2019 Jul; 66(7):e27510. PubMed ID: 30406959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
